Degree | Type | Year |
---|---|---|
2502445 Veterinary Medicine | OT | 5 |
You can view this information at the end of this document.
It is advised to have passed the Pharmacology curriculum (3rd year veterinary graduate students) or to have attended a basic or applied pharmacology course.
The Overall Objective is that the student acknowledges the rigor behind human and animal medicines approval and that such knowledge may be of use no matter the professional choice, including the pharmaceutical industry which is very unknown for them (human or veterinary industry).
The Specific Objectives are:
- that the student understand the scientific rationale behind the studies needed for medicines approval:quality, efficacy and safety (used in human and animals) 30%
- that the student acknowledges the benefit-to-risk concept as a key paradigm in health sciences 10%
- that the student questions the recommendations for medicines approval and holds the ability to debate and propose alternative approaches 15%
- that the student acquires knowledge on pharmaceutical companies corporate organization to undertake research and marketing of medicines 20%
- that the student understands that regulation is science and that it offers reassurance to patients 10%
- raise awareness for futur clinicians of the need to follow up the therapeutic performance of marketed medicines (pharmacovigilance) 5%
- that the student includes the pharmaceutical industry for her/his professional development based on the clear added value 10%
Live teaching: 26 hours per student
- 22 hours interactive theoretical sessions
- 2 hours: projects presentation
- 2 hours: visit to pharmaceutical company
+ Student's project + individual/team supervised work
Syllabus
Medicines R+D put into context
- Objectives of the course and sessions dynamics
- Brainstorming: R+D rationale
- Healthcare authroties role: regulation is science
- Recap: R+D steps
Setting up the project
- Projects setup
- Teams set up: subject per team
- Explanation of project execution
Discovery phase
- sources of identification and information of new molecules
Preclinical studies (1): objective and design
- Objectives of preclinical studies.
- Efficacy studies:Target identification and validation. Biological and in silico systems
Preclinical studies (2): toxicity
- Safety pre-assessmnt: Characterization of toxicity.
- NOAEL. Genotoxicity, Immunotoxicicty, etc
Production and formulation of medicines + quality control (1)
- Medicines manufacturing: chemically synthesized and biologics.
- Phases: active substance characterization.
- Formulation
Production and formulation of medicines + quality control (2)
Projects presentation - Debate
- Presentation : teams
- Feed back
- Assessment
Clinical studies: Objectives
- Objectives of clinical research - Design rationale
- Phase I (First-in-human): PK, safety and tolerability
- Objectives and execution
Patient studies
Innovators – Biosimilars etc
Veterinary medicines development
Biopharmaceutical industry
Overview
Projects exhibition
Title | Hours | ECTS | Learning Outcomes |
---|---|---|---|
Type: Directed | |||
Field sessions | 2 | 0.08 | 4, 7 |
Seminars | 2 | 0.08 | 15, 2, 4, 5, 7, 11, 14 |
Theoretical sessions | 22 | 0.88 | 1, 4, 5, 7, 8, 10, 11, 3, 14, 13, 16 |
Type: Supervised | |||
Tutorials | 12 | 0.48 | 1, 4, 5, 7, 8, 10, 11, 3, 14, 13, 16 |
Annotation: Within the schedule set by the centre or degree programme, 15 minutes of one class will be reserved for students to evaluate their lecturers and their courses or modules through questionnaires.
Title | Weighting | Hours | ECTS | Learning Outcomes |
---|---|---|---|---|
Engagement-participation (engagement in questioning and debating) | 30% | 0 | 0 | 1, 15, 2, 4, 5, 6, 7, 8, 10, 12, 11, 3, 14, 13, 16 |
MCQ Exam (30% of final mark) | 30% | 12 | 0.48 | 1, 15, 2, 4, 5, 6, 7, 8, 10, 12, 11, 14, 13, 9, 16 |
Team work (written + presentation) | 40% | 25 | 1 | 1, 15, 4, 5, 7, 11, 14, 13, 9 |
IN THIS COURSE THE "SINGLE ASSESSMENT SYSTEM" IS NOT CONSIDERED
ACTIVITY 1 -Team Work (TeE): 40% of the final mark. The TeE grade will be made up of a Written Report (50%) and an Oral Presentation (50%). The members of the same team will have the same grade in the Work regardless of their contribution to it.
ACTIVITY 2 - Intervention in class (IeC): 30% of the final mark. The IeC mark can be (a) 10/10: intervenes (i.e. asks or gives an opinion spontaneously) in all or the vast majority of classes, (b) 7.5/10: intervenes frequently in most classes , (c) 5/10: intervenes sometimes, usually coming to class, (d) 2.5/10: intervenes rarely even though he attends class, and (e) 0/10: attends class very little or, even if he does attend, usually does not intervene except by direct questions from the teacher. Class attendance is NOT evaluated, although it should be remembered that low attendance prevents frequent intervention.
ACTIVITY 3 - Class Exam (EeC): 30% of the final grade. It can be exclusively multiple choice, or a combination of multiple choice and short question/s (hybrid), and never last more than 1 hour. Questions about all the content of the subject, including the Works presented by others, the interventions of invited directors or the visit to the Pharmaceutical Laboratory.
The final mark will result from the weighted average of the three evaluated activities.
Explanatory Notes
Team work: • The student will demonstrate the skills acquired throughout the course program by delivering a written team work and presenting it.
MANDATORY • Mandatory to attend (1) sessions with industry executives (2 sessions), (2) visit a production facility (1 session) and (3) work presentation (1 session) ES OBLIGATORIA.
Not attending one of those session would preclude from passing (unles justified ahead with a written document)
Attending theoretical sessions is not mandatory, but it is advised not to skip many of those sessions given that class interaction and participation is relevant to pass
NO ASSESSMENT
If the student does not comply with one of the following criteria, the subject will not be assessed and therefore will be passed:
- attend all the mandatory sessions
- attend and deliver the exam
- execute the team work (proved by the signing of the work or the appearance of her/his name on it)
- orally presenting the team work (co-presentation)
Se entregará a principio de curso.
No software is used
Name | Group | Language | Semester | Turn |
---|---|---|---|---|
(SEM) Seminars | 1 | Spanish | second semester | morning-mixed |
(TE) Theory | 1 | Spanish | second semester | morning-mixed |